Condition: RSV Respiratory Syncytial Virus · Sponsor: AstraZeneca
This Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Long Beach, California, United States | Recruiting |
| Research Site | Rolling Hills Estates, California, United States | Recruiting |
| Research Site | Chicago, Illinois, United States | Recruiting |
| Research Site | Lenexa, Kansas, United States | Recruiting |
| Research Site | Kansas City, Missouri, United States | Recruiting |
| Research Site | Omaha, Nebraska, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07717840